Qure.ai
PrivateLast Round
Grant
Jan 21, 2026
Est. Valuation
$145.17M
Total Funding Raised
$117.49M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Qure.ai is a health technology company that develops AI-powered radiology interpretation solutions to automate the analysis of medical images such as X-rays, CT scans, and MRIs for faster and more accurate disease diagnosis.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Healthcare Analytics, Computer Vision
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Qure.ai Comparables
Compare Qure.ai with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Harrison.ai | 87% | |
| Aidoc | 84% | |
| Infervision | 84% |
Qure.ai Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 21, 2026 | ||||
| IPO | May 20, 2025 | ||||
| Series D | Sep 24, 2024 | ||||
| Series C | Mar 28, 2022 | ||||
| Grant | Feb 7, 2022 | ||||
VC Round | Feb 27, 2020 |
Key People
Founding team and executive leadership
Qure.ai Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fractal Analytics | Series C, VC Round |
| Merck Global Health Innovation Fund | Series D |
| MassMutual Ventures Southeast Asia | Series C, VC Round |
| NHS Cancer Programme | Grant |
| Peak XV Partners | VC Round |
| SBRI Healthcare | Grant |
| 360 ONE Asset | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 29, 2026
Technology has impacted over 22 million patients in 90+ countries.
- Jun 29, 2026
Received 13 FDA clearances and 62 CE markings.
Recent news
Latest coverage and updates
- hiresOct 15, 2026
Qure appoints Rohit Mani as Marketing Director, Brand & Social on Oct 15th '26, with a remit covering brand positioning, content narratives, and social media strategy across international markets.
- hiresOct 12, 2026
Qure hires Vaibhav Mehta as Chief Legal Officer in October 2026
- recognized_asSep 18, 2026
Qure recognized as Class IIb CE certification under the EU Medical Device Regulation on Sep 18th '26.
- hiresAug 26, 2026
Qure appoints Mihir Bhanushali as Executive Vice President, Global Health, to expand AI-powered healthcare and frontline care across Africa, Southeast Asia, South Asia, and Latin America in India on Aug 26th '26.
Qure.ai Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Qure.ai's valuation, stock price, and market status.
Is Qure.ai a public or private company?
Qure.ai is a private company.
What is the current stock price of Qure.ai?
Qure.ai is a private company, so its shares have no public market price. Caplight tracks Qure.ai's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Qure.ai worth (valuation)?
Qure.ai's valuation is estimated at $145.2M based on funding round data.
Can I buy Qure.ai stock?
Qure.ai shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Qure.ai's last funding round?
Qure.ai's most recent funding round was Grant on January 21, 2026.
Who are the main investors in Qure.ai?
Key investors in Qure.ai include Peak XV Partners, 360 ONE Asset, Gates Foundation, Novo Holdings, 360 ONE Asset Management Limited.
Will Qure.ai IPO soon?
No public IPO plans have been announced for Qure.ai.
How can I track Qure.ai secondary market activity?
Caplight tracks bids, offers, and trades in Qure.ai's shares on secondary markets.